To date, both CAML and CHC levels have been demonstrated to correlate with survival and treatment outcomes, and treatment-related protein expression pattern changes in primary tumors have been shown to reflect in their CHC counterparts. The gene discussed is CAMLG; the disease is cryohydrocytosis.